Theyll tailor a treatment plan and order a lab test if metabolic data is needed
3 min read FDA Moves to End Compounded Semaglutide and Tirzepatide What It Means for Weight Loss Patients The FDA Just Proposed a Major Change to Compounded Weight Loss Drugs If you've been following the news about weight loss medications, you may have heard that the FDA announced a significant regulatory change on April 30, 2026
However, there are certain contraindications and precautions to keep in mind when considering semaglutide treatment
These drugs offer substantial potential health benefits, but the combination of intense demand, new uses, and high prices for these treatments is likely to place tremendous pressure on Medicare spending, Part D plan costs, and premiums for Part D coverage.
Obesity A recent meta-analysis, summarized studies focused on LC supplementation for a prolonged time (median 3 months) [40]
If needed, they may order a metabolic lab test to better understand your hormone and metabolic health or support insurance coverage